FKBPL and ankylosing spondylitis: Besides, based on the results of PheWAS, the potential benefits of FKBPL inhibitors for the treatment of ankylosing spondylitis appear to be much lower than the side effects they may cause (FKBPL inhibitors may cause up to 58 adverse reactions, including tumors, endocrine system, gastrointestinal system, and other related disorders, with a therapeutic effect in only 5 diseases).